{"description":"Documents matching 'telemedicine', published on or after 01/01/2026, and from Drug Enforcement Administration","count":3,"total_pages":1,"results":[{"title":"Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.","document_number":"2026-22843","html_url":"https://www.federalregister.gov/documents/2026/11/10/2026-22843/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22843.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22843.pdf?1794231909","publication_date":"2026-11-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"sale), d,l-amphetamine, lisdexamfetamine, and methylphenidate, which are prescribed to treat patients with attention deficit hyperactivity disorder (ADHD), from calendar year 2026 levels. FDA also raised concerns over drug shortages potentially related to the growth in <span class=\"match\">telemedicine</span>, supply chain issues, manufacturing and quality issues, and business decisions of manufacturers, which DEA considered in developing the proposed 2027 APQ. DEA recently proposed to increase the 2026 APQs for both lisdexamfetamine and methylphenidate (for sale) and is proposing"},{"title":"Muhamad Aly Rifai, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-21258","html_url":"https://www.federalregister.gov/documents/2026/10/19/2026-21258/muhamad-aly-rifai-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-19/pdf/2026-21258.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-21258.pdf?1792154712","publication_date":"2026-10-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Patient Health Questionnaire (PHQ-9); GAD-7 Anxiety; and Adult ADHD Self-Report Scale Symptom Checklist. RFAAX 32, at 1-38. Additionally, Respondent submitted the following documentation: Psychiatric Progress Notes indicating an in-person appointment on May 17, 2021; a video <span class=\"match\">telemedicine</span> follow-up on June 11, 2021; and a telehealth appointment on August 9, 2021; Urine Drug Screen—12 Panel Integrated Test Cup with results dated August 9, 2021; a letter dated August 9, 2021, to UC informing her that Respondent can no longer provide UC with psychiatric services"},{"title":"Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment","type":"Rule","abstract":"The \"Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (the SUPPORT Act),\" which became law on October 24, 2018, amended the Controlled Substances Act to expand the conditions a practitioner must meet to provide medication-assisted treatment for opioid use disorder and expand the options available for a physician to be considered a qualifying physician. The SUPPORT Act also allowed a pharmacy to deliver prescribed controlled substances to a practitioner's registered location for the purpose of maintenance or detoxification treatment to be administered under certain conditions by a practitioner. The Drug Enforcement Administration promulgated an interim final rule with request for comments in November 2020 to amend its regulations to make them consistent with the SUPPORT Act and implement its requirements. On December 29, 2022, the Restoring Hope for Mental Health and Well-Being Act of 2022 removed many of the statutory provisions of the SUPPORT Act. This final rule adopts the provisions of the interim final rule that are still applicable as final, with minor changes. In addition, this final rule implements the related provisions of the Restoring Hope for Mental Health and Well-Being Act of 2022.","document_number":"2026-11526","html_url":"https://www.federalregister.gov/documents/2026/06/09/2026-11526/implementation-of-the-substance-use-disorder-prevention-that-promotes-opioid-recovery-and-treatment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-09/pdf/2026-11526.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-11526.pdf?1780922715","publication_date":"2026-06-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"disruptions in care when a DATA-waived practitioner is unavailable to administer the substance. The commenters maintained that this clarification will have a positive effect on patients in rural areas and in residential care facilities, and those receiving regular treatment via <span class=\"match\">telemedicine</span>, during natural disasters and during pandemics. \n \n DEA Response 3: \n As noted by three commenters, the CSA's definition of “practitioner” includes a “pharmacy . . . or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction"}]}